Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.33 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in ependymal cells | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 217 | 0.82 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 1031
Sealed predictions
- DYRK1B in dopamine neurons, braak-0.48 (p 0.187) → -0.26 (p 0.504)receipt 1037
Swarm cases
receipt 1037: DYRK1B in dopamine neurons, braak
- power
- full sample -0.41 (p 0.093, n 18), 95% CI -0.73 to +0.07. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.43 (p 0.075, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.47 (p 0.047, n 18). not the mix.
- skeptic
- leave-one-out range -0.48 to -0.33, sign flips 0; without severely affected donors -0.41 (p 0.093, n 18). robust.
- cell type
- strongest in microglia: -0.60 (p 0.0083, n 18) vs -0.41 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DYRK1B in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up DYRK1B · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.13 p 0.657 (needs p < 0.0013)
Receipts
loading the receipts